Domperidone
- Generic Name
- Domperidone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24ClN5O2
- CAS Number
- 57808-66-9
- Unique Ingredient Identifier
- 5587267Z69
- Background
A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
- Indication
For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
- Associated Conditions
- Diabetic Gastroparesis, Dyspepsia, Erosive Esophagitis, Gastrointestinal Symptoms, Non-erosive Reflux Esophagitis Disease (NERD), Upper gastrointestinal motility disorders
- Associated Therapies
- -
Use of Domperidone for Treatment of Upper Gastrointestinal Disorders
- Conditions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Palo Alto Medical Foundation
- Registration Number
- NCT03128398
Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2017-01-16
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03022201
- Locations
- 🇰🇷
Cheol Min Shin, Seongnam-si, Gyeonggi-do, Korea, Republic of
Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants
- First Posted Date
- 2016-06-29
- Last Posted Date
- 2016-11-25
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02816853
Domperidone for Chronic Nausea and Vomiting
- Conditions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- Yehudith Assouline-Dayan
- Registration Number
- NCT02757534
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis
- Conditions
- Interventions
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 10
- Registration Number
- NCT02699385
Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Prasanna K Kapavarapu
- Registration Number
- NCT02567175
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Domperidone and Risk of Sudden Cardiac Death
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2024-02-09
- Target Recruit Count
- 214962
- Registration Number
- NCT02500108
- Locations
- 🇨🇦
Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada
Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 17
- Registration Number
- NCT02493049
- Locations
- 🇨🇦
Calgary MS Clinic at Foothills Medical Centre, Calgary, Alberta, Canada
Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 64
- Registration Number
- NCT02308137
- Locations
- 🇨🇦
Calgary MS Clinic at Foothills Medical Centre, Calgary, Alberta, Canada
Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Liangzhou Wei
- Target Recruit Count
- 60
- Registration Number
- NCT02264587
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.